{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:02:05Z","timestamp":1771628525246,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40259-017-0220-y","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T10:20:59Z","timestamp":1492597259000},"page":"167-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook"],"prefix":"10.1007","volume":"31","author":[{"given":"Belinda","family":"Di Bartolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Psaltis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"220_CR1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"220_CR2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","volume":"46","author":"P Libby","year":"2005","unstructured":"Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"220_CR3","doi-asserted-by":"crossref","first-page":"e001800","DOI":"10.1161\/JAHA.112.001800","volume":"1","author":"PH Jones","year":"2012","unstructured":"Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1:e001800.","journal-title":"J Am Heart Assoc"},{"key":"220_CR4","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012\u201322.","journal-title":"Eur Heart J"},{"key":"220_CR5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"220_CR6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","volume":"14","author":"D Cunningham","year":"2007","unstructured":"Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14:413\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"220_CR7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022\u201336.","journal-title":"Circ Res"},{"key":"220_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136.","journal-title":"Nat Genet"},{"key":"220_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161\u20135.","journal-title":"Nat Genet"},{"key":"220_CR10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"AJ Hooper","year":"2007","unstructured":"Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193:445\u20138.","journal-title":"Atherosclerosis"},{"key":"220_CR11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley THJ, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372.","journal-title":"N Engl J Med"},{"key":"220_CR12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514\u201323.","journal-title":"Am J Hum Genet"},{"key":"220_CR13","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144\u201353.","journal-title":"N Engl J Med"},{"key":"220_CR14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","volume":"48","author":"MJ Graham","year":"2007","unstructured":"Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48:763\u20137.","journal-title":"J Lipid Res"},{"key":"220_CR15","doi-asserted-by":"crossref","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","volume":"286","author":"F Du","year":"2011","unstructured":"Du F, Hui Y, Zhang M, et al. Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein. J Biol Chem. 2011;286:43054\u201361.","journal-title":"J Biol Chem"},{"key":"220_CR16","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","volume":"106","author":"JCY Chan","year":"2009","unstructured":"Chan JCY, Piper DE, Cao Q, et al. A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106:9820\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"220_CR17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","volume":"228","author":"AL Catapano","year":"2013","unstructured":"Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228:18\u201328.","journal-title":"Atherosclerosis"},{"key":"220_CR18","doi-asserted-by":"crossref","first-page":"906.e913","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906.e913\u2013915.e913.","journal-title":"Am Heart J"},{"key":"220_CR19","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"220_CR20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108\u201318.","journal-title":"N Engl J Med"},{"key":"220_CR21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"220_CR22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","volume":"115","author":"CM Ballantyne","year":"2015","unstructured":"Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212\u201321.","journal-title":"Am J Cardiol"},{"key":"220_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","volume":"119","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Watts GF, Robinson JG, et al. Effect of alirocumab on lipoprotein(a) over \u22651.5\u00a0years (from the phase 3 ODYSSEY program). Am J Cardiol. 2017;119:40\u20136.","journal-title":"Am J Cardiol"},{"key":"220_CR24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","volume":"135","author":"G Reyes-Soffer","year":"2017","unstructured":"Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135:352\u201362.","journal-title":"Circulation"},{"key":"220_CR25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","volume":"57","author":"FJ Raal","year":"2016","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role. J Lipid Res. 2016;57:1086\u201396.","journal-title":"J Lipid Res"},{"key":"220_CR26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","volume":"135","author":"GF Watts","year":"2017","unstructured":"Watts GF, Chan DC, Dent R, et al. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation. 2017;135:338\u201351.","journal-title":"Circulation"},{"key":"220_CR27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","volume":"133","author":"SD Ferranti de","year":"2016","unstructured":"de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016;133:1067\u201372.","journal-title":"Circulation"},{"key":"220_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccl.2015.01.001","volume":"33","author":"VE Bouhairie","year":"2015","unstructured":"Bouhairie VE, Goldberg AC. Familial hypercholesterolemia. Cardiol Clin. 2015;33:169\u201379.","journal-title":"Cardiol Clin"},{"key":"220_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2014","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2014;385:331\u201340.","journal-title":"Lancet"},{"key":"220_CR30","first-page":"2996","volume":"36","author":"JJP Kastelein","year":"2015","unstructured":"Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.","journal-title":"Eur Heart J"},{"key":"220_CR31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341\u201350.","journal-title":"Lancet"},{"issue":"48","key":"220_CR32","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37(48):3588\u201395.","journal-title":"Eur Heart J"},{"key":"220_CR33","first-page":"485","volume":"21","author":"DF Blackburn","year":"2005","unstructured":"Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21:485\u20138.","journal-title":"Can J Cardiol"},{"key":"220_CR34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5694\/j.1326-5377.1996.tb94138.x","volume":"164","author":"LA Simons","year":"1996","unstructured":"Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208\u201311.","journal-title":"Med J Aust"},{"key":"220_CR35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","volume":"165","author":"RH Chapman","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147\u201352.","journal-title":"Arch Intern Med"},{"key":"220_CR36","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395\u2013410.","journal-title":"J Am Coll Cardiol"},{"key":"220_CR37","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to pcsk9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497\u2013506.","journal-title":"JAMA"},{"key":"220_CR38","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"220_CR39","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580\u201390.","journal-title":"JAMA"},{"key":"220_CR40","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758\u201369.","journal-title":"J Clin Lipidol"},{"key":"220_CR41","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078\u201387.","journal-title":"N Engl J Med"},{"key":"220_CR42","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556\u201365.","journal-title":"JAMA"},{"key":"220_CR43","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373\u201384.","journal-title":"JAMA"},{"key":"220_CR44","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","volume":"134","author":"KK Ray","year":"2016","unstructured":"Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation. 2016;134:1931\u201343.","journal-title":"Circulation"},{"key":"220_CR45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","volume":"173","author":"MS Sabatine","year":"2016","unstructured":"Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016;173:94\u2013101.","journal-title":"Am Heart J"},{"key":"220_CR46","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. [Epub 2017 Mar 17]. doi: 10.1056\/NEJMoa1615664 .","DOI":"10.1056\/NEJMoa1615664"},{"key":"220_CR47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","volume":"178","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Amarenco P, Brunell R, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) lipid lowering and SPIRE cardiovascular outcomes trials. Am Heart J. 2016;178:135\u201344.","journal-title":"Am Heart J"},{"key":"220_CR48","doi-asserted-by":"publisher","unstructured":"Ridker PM, Revkin J, Amarenco P, et al.; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. [Epub 2017 Mar 17]. doi: 10.1056\/NEJMoa1701488 .","DOI":"10.1056\/NEJMoa1701488"},{"key":"220_CR49","doi-asserted-by":"crossref","first-page":"682.e681","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168:682.e681\u2013689.e681.","journal-title":"Am Heart J"},{"key":"220_CR50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234\u201343.","journal-title":"Circulation"},{"key":"220_CR51","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"key":"220_CR52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, et al. Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-a cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol. 2017;40:59\u201365.","journal-title":"Clin Cardiol"},{"key":"220_CR53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of pcsk9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743\u201353.","journal-title":"JAMA"},{"key":"220_CR54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41\u201351.","journal-title":"N Engl J Med"},{"issue":"15","key":"220_CR55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0220-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T04:55:43Z","timestamp":1569041743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0220-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0220-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}